Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Martine Neyens"'
Autor:
Anna Dari, Philippe Jacqmin, Yuki Iwaki, Martine Neyens, Mathieu Le Gars, Jerald Sadoff, Karin Hardt, Javier Ruiz‐Guiñazú, Juan José Pérez‐Ruixo
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 10, Pp 1485-1498 (2023)
Abstract Mechanistic model‐based simulations can be deployed to project the persistence of humoral immune response following vaccination. We used this approach to project the antibody persistence through 24 months from the data pooled across five c
Externí odkaz:
https://doaj.org/article/e5c516261c6749c5aae3b158bce0490e
Autor:
Anna Dari, Muriel Boulton, Martine Neyens, Mathieu Le Gars, Belén Valenzuela, Georgi Shukarev, Vicky Cárdenas, Javier Ruiz‐Guiñazú, Jerald Sadoff, Richard M. W. Hoetelmans, Juan José Pérez Ruixo
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:380-389
Understanding persistence of humoral immune responses elicited by vaccination against coronavirus disease 2019 (COVID-19) is critical for informing the duration of protection and appropriate booster timing. We developed a mechanistic model to charact
Autor:
Juan-José Pérez-Ruixo, Yaowei Zhu, Martine Neyens, Marie-Helene Jouvin, Sindhu Ramchandren, Yan Xu, Jocelyn Leu, Anne-Gaëlle Dosne, Yuan Xiong, Belén Valenzuela, Leona Ling, Partha Nandy, Hong Sun
Publikováno v:
Sunday, April 23.
Autor:
Hiroko Shimizu, Marc De Meulder, Bart Remmerie, Yuko Tsukamoto, Mahesh N. Samtani, Srihari Gopal, Martine Neyens
Publikováno v:
Clinical Pharmacology in Drug Development
The paliperidone pharmacokinetics after intramuscular administration of once‐monthly paliperidone palmitate in Japanese patients were studied in 3 phase 1 studies and in 2 phase 3 studies performed in Japan, Korea, and Taiwan. These data (Japanese,
Publikováno v:
The Journal of antimicrobial chemotherapy. 76(12)
Objectives To characterize the population pharmacokinetics of the rilpivirine long-acting (LA) formulation after intramuscular administration. Methods Rich and sparse rilpivirine plasma concentration data were obtained from seven clinical studies. In
Autor:
Andre Goy, Mariya Salman, Italo Poggesi, Simon Rule, Michelle Mahler, Graeme Fraser, Olga Samoilova, Angela Howes, Paula Cramer, Siddhartha Ganguly, Javier Loscertales, Nancy L. Bartlett, Martine Neyens, Silvia Maria Lavezzi, Giuseppe De Nicolao, Fatih Demirkan, Jan de Jong, Marie Sarah Dilhuydy, Abraham Avigdor
Publikováno v:
Pharmaceutical Research. 36
In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we describe the pharmacokinetic (PK) observat
Autor:
David A. Margolis, Peter Williams, Kelong Han, Susan L. Ford, Krischan J Hudson, Parul Patel, Herta Crauwels, Mark Baker, Sandy Griffith, William Spreen, Stefaan Rossenu, Martine Neyens
Publikováno v:
Open Forum Infectious Diseases
Background Monthly injectable CAB LA + RPV LA was noninferior to daily oral 3-drug antiretroviral therapy in HIV-1 virologically suppressed adults. CAB and RPV pharmacokinetics (PK) were assessed during the 48 Week maintenance period of the ATLAS and
Autor:
Eef Hoeben, Adrian Dunne, An Vermeulen, Damayanthi Devineni, Willem de Winter, Martine Neyens
Publikováno v:
Clinical Pharmacokinetics. 55:209-223
Canagliflozin is an orally active, reversible, selective sodium-glucose co-transporter-2 inhibitor. A population pharmacokinetic (popPK) model of canagliflozin, including relevant covariates as sources of inter-individual variability, was developed t
Autor:
Martine Neyens, José Pinheiro, Shiferaw Mariam, Chyi-Hung Hsu, Adrian Dunne, Willem de Winter, Xavier Woot de Trixhe
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 42:417-426
The computational effort required to fit the pharmacodynamic (PD) part of a pharmacokinetic/pharmacodynamic (PK/PD) model can be considerable if the differential equations describing the model are solved numerically. This burden can be greatly reduce
Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial
Autor:
Martine Neyens, Simon Rule, Giuseppe De Nicolao, Mariya Salman, Javier Loscertales, Abraham Avigdor, Italo Poggesi, Andre Goy, Michelle Mahler, Marie-Sarah Dilhuydy, Siddhartha Ganguly, Angela Howes, Olga Samoilova, Fatih Demirkan, Jan de Jong, Graeme Fraser, Alexander Pristupa, Silvia Maria Lavezzi, Nancy L. Bartlett, Paula Cramer
Background: Ibrutinib, an inhibitor of Bruton's tyrosine kinase, is indicated for the treatment of several B-cell malignancies. In the phase 3 HELIOS trial, the addition of ibrutinib to a bendamustine plus rituximab regimen significantly improved pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de497f7784ec1470c104cce5bd93ec15
https://avesis.deu.edu.tr/publication/details/ce8269ce-4e58-4d62-8ca5-d92bc489e843/oai
https://avesis.deu.edu.tr/publication/details/ce8269ce-4e58-4d62-8ca5-d92bc489e843/oai